Article Talk: 5 Questions With a Physician on Improving Treatment of Pancreatic Cancer

Started by Gobbler, August 28, 2016
2 replies for this topic
Gobbler

Member
558 Posts
Posted on
August 28, 2016
One of the major challenges, I'm told, in pancreatic cancer are the limited number of patients who actually qualify for a clinical trial OR who can actually get to a clinical trial. In my case, I was diagnosed with Stage 2B adenocarcinoma of the tail of my pancreas (4cm) with 5/12 regional lymph node involvement. I had a distal pancreatectomy/spleenectomy with 60% of my pancreas removed on 7/10/14 followed by a course of 26 gemcitabine with 6 1/2 weeks of 5FU/chemo radiation and have not had a recurrence. Should the cancer return, I am limited in terms of participation in a clinical trial because of my responsibilities and locality. I am a caregiver for my wife who had a stroke and we live in South Dakota. I cannot put my wife in a nursing home, sell my home and farm and move to Baltimore or Houston to participate in a clinical trial. That leaves me with two choices.........take a chance on local treatment or die. Why are there NO COLLABORATIVE CLINICAL TRIALS where my local oncologist administers the prescribed trial treatment, monitors the outcomes, and reports the results to the clinical trial sponsors. If science is EVER going to rid us of this NASTY, TERRIBLE DISEASE, they need to implement a national collaborative clinical trial system so vastly many more patients can participate where we can get more answers quickly to more people. In this day and age of high tech computers, genetics, chemistry, and pharmaceutical mouse click away from having answers! Without COLLABORATIVE CLINICAL TRIALS and information sharing, it gives a new meaning to "you can't get there from here"! John G. Moisan (Pancreatic Cancer Survivor - 2 years, 1 month and 18 days)
Report

Page 1 of 1 1

amanparker

Member
0 Replies
Posted on
December 21, 2019
I would like you to inform about the an Experimental therapy carried out by Dr. Conan Kinsey of Huntsman Cancer Institute. The physician-scientist discovered that 2 drugs Trametinib and Hydroxychloroquine. run 3 free These drugs could potentially affect the process of abnormal cell division as well as growth caused by a genetic mutation, increasing a patient
Report
Clara Tarris

Member
0 Replies
Posted on
February 14, 2020
Pancreatic cancer is rare but often aggressive. Associated with many risk factors, pancreatic cancer generally affects men from the age of 50. Doctissimo takes stock of pancreatic cancer, its diagnosis and the treatment planned. Clara from guide produits soins et beaut

Page 1 of 1 1

You must log in to use this feature, please click here to login.